
Abivax, Moderna, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that use biological science and technology to develop drugs, therapies, diagnostics, and related healthcare products, offering investors exposure to advances in medical research. They tend to be highly volatile and risky because company valuations often hinge on binary events such as clinical trial results and regulatory approvals, which can rapidly change prospects and share prices. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Abivax (ABVX)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read Our Latest Research Report on MRNA
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read Our Latest Research Report on DHR
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in December 2025
- Instacart Got Caught Surveillance Pricing… But Investors Didn’t Care
- Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength
- Amazon Now Delivery Push Could Boost Its 2026 Outlook
- 5 Small-Cap Stocks to Watch in 2026 as Investors Rotate Out of Big Tech
- 3 Analyst-Backed Stocks the Market Is Getting Totally Wrong
